North Run Capital’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

North Run Capital’s Portfolio MNTA Stock Details MNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-705,000	Closed	-$8.24M	–	26
2016 Q3	$8.24M	Sell	705,000 -82,500	-10%	-$970K	1.29%	23
2016 Q2	$8.51M	Buy	787,500 +719,962	+1,066%	+$7.43M	1.4%	20
2016 Q1	$624K	Buy	+67,538	New	+$727K	0.09%	28

Other funds holding MNTA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

North Run Capital's MNTA Position: Q4 2016 in Review

North Run Capital sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q4 2016, closing a stake of 705,000 shares — an estimated $8.24M sold.

North Run Capital first reported a position in MNTA in Q1 2016 and held it in 3 quarters. The position peaked at $8.51M in Q2 2016. 160 funds tracked by Wall St. Rank hold MNTA as of Q4 2016.

North Run Capital reported no remaining Momenta Pharmaceuticals, Inc. position as of Q4 2016 after selling out during the quarter.
North Run Capital sold 705,000 Momenta Pharmaceuticals, Inc. shares in Q4 2016, an estimated $8.24M.
North Run Capital first reported a position in Momenta Pharmaceuticals, Inc. in Q1 2016 and held it in 3 quarters.
North Run Capital's Momenta Pharmaceuticals, Inc. position peaked at $8.51M in Q2 2016.
160 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q4 2016.

Based on North Run Capital's 13F filing for Q4 2016, filed 10 Feb 2017.